Lewis S. Gruber is Chief Executive Officer, Chief Scientific Officer and co-founder of SIWA. Prior to co-founding SIWA in 2006, he was a founder of Arryx, Inc., and was its CEO from 2000 through 2005 (acquired by a publicly-held company). While Mr. Gruber was at Arryx, it received numerous awards including ones for World Economic Forum Technology Pioneer (2005) and Red Herring Top 100 Innovator for 2004. Prior to that, he became CEO and a member of the Board of Hyseq, Inc. from 1994 through 2000. While CEO of that company, he completed the largest initial public offering of a biotechnology company in 1997 as well as collaborations totaling over $102 million. He is the inventor of all of SIWA’s issued patents and a co-inventor on numerous others. Mr. Gruber was a patent attorney for many years before becoming an entrepreneur. He has spoken at numerous conferences including most recently, the Third Annual Conference on the Governance of Emerging Technologies: Law, Policy and Ethics Session on Anti-Aging Technologies and Stem Cells Regenerative Medicine Congress 2015. In addition to a J.D., he has an M.S. in biology. Mr. Gruber serves on the board of the Field Museum of Natural History, and is a member of the Visiting Committee of the Oriental Institute at the University of Chicago and the Madison Council of the Library of Congress.
Misty Gruber is the Chief Financial and Scientific Affairs Officer/General Counsel and a member of the Board of SIWA. Prior to co-founding SIWA, Ms. Gruber served as Co-Chair of the biotechnology section of law the Dykema Gossett PLLC law firm, with a focus in corporate governance, mergers and acquisitions and securities law matters, including private and public securities offerings. Over her almost thirty years as an attorney, she represented issuers, investors, underwriters and venture capital companies. She also was licensed as a CPA in Arizona for several years. Ms. Gruber was a co-founder of Arryx, Inc. and a co-founder and initial member of the Board of Hyseq, Inc. (after going public, it was subsequently merged into another public company). Ms. Gruber is a member of the Visiting Committee of the Oriental Institute at the University of Chicago and the Madison Council of the Library of Congress. In addition to a J.D., she has an M.S. in biology.
John O. Peters III is the Chairman of the Board of SIWA. Mr. Peters is a former financial executive with over 30 years of experience in several different industries including technology, manufacturing and government services. Most recently he was a founder, board member and the original chief financial officer of Triple Canopy, Inc., one of the world’s largest private security firms providing high end services to the United States Government and commercial companies operating in high risk environments. Triple Canopy, now Constelis, was successfully sold to a private equity firm in 2015. Mr. Peters is a CPA and has a BBA from Loyola University of Chicago and an MBA from the University of Chicago. He is a member of the AICPA. Mr. Peters works with several charitable institutions. He is a knight of the Holy Sepulcher of Jerusalem and is joining the Visiting Committee of the Oriental Institute at the University of Chicago.
James Alvarez is a member of the Board of SIWA. Prior to joining SIWA, Mr. Alvarez founded Gesture in May of 2011. Over the next 7 years, Gesture would go on to support over 5,500 charity events and helped charity partners raise over $1 billion dollars. Gesture was successfully acquired in November 2017. Prior to Gesture, Mr. Alvarez was the founder of 5 other companies. He has a B.S. from Indiana University.
Alex Kormushoff is a member of the Board of SIWA. Over a 30-year career, Mr. Kormushoff has been at the forefront of important technology trends in the fields of predictive analytics, healthcare technology, and information technology. Most recently, Alex was the President of Strategic Healthcare Programs a company that provides real-time analytics solutions for the healthcare industry. At SHP, Alex was responsible for all aspects of the business and he led the successful exit of SHP in August of 2014. Previously, Alex was the Executive Director of Accenture Analytics where he led the Global Health and Public Service Market. Additionally, he was responsible for all investment activity across Accenture Analytics.
Scientific Advisory Board
John Ford, Ph.D. – Member of SIWA Scientific Advisory Board; Senior Scientific Consultant. Dr. Ford has extensive drug discovery, development, lifecycle management and business development experience from roles at both start-up and global biopharmaceutical companies. He has a proven record of building successful companies, biomedical research and business development. John led drug discovery/development efforts at Hyseq Inc. and Genset SA and was responsible for initiating and/or managing 9 preclinical programs (including discovery of anti-inflammatory cytokines IL- 36 and IL-38). At Takeda Pharmaceuticals, he participated in 4 drug launches, lifecycle management research for 5 marketed drugs and helped to initiate two clinical trials for new oncology indications for a monoclonal antibody drug. In addition, he helped to establish and operate the US portion of a global business development and research sourcing program providing 38 business development leads and supporting 20 internal early-stage research programs. He also assisted in the evaluation of an instrument to fund high-risk internal programs through venture capital investors. Dr. Ford is a Senior Medical Science Liaison at Agios Pharmaceuticals.
Stuart Kupfer, M.D. – Member of SIWA Scientific Advisory Board; Senior Scientific Consultant. Dr. Kupfer is a physician-scientist with extensive leadership experience in clinical and business development strategy and clinical and basic research. He has 19 years of experience in pharmaceutical development of novel agents in multiple therapeutic areas in collaboration with FDA, EMA, and PMDA, leading to numerous global regulatory approvals. Most recently, Dr. Kupfer spent 12 years at Takeda, holding positions of increasing responsibility as Senior Medical Director, Executive Medical Director, and VP Therapeutic Area Head, with accountability for the clinical development portfolio in the cardiovascular and metabolic therapeutic area. Among other experience, he served as Assistant Professor at Washington University in St. Louis leading research programs to investigate immunomodulators of osteoclast function and gene regulation of steroid hormone receptors. Dr. Kupfer has also practiced and taught clinical endocrinology and diabetes in academic hospital settings.
Thomas Tang, PhD. – Member of SIWA Scientific Advisory Board; Dr. Tang, a founder and CEO of First Dimension BioSciences, is an inventor and informatics scientist with over 20 years of experience in genomics and bioinformatics research, as well as product development. He has published over 25 research papers and has procured 90 issued US patents. Dr. Tang has led US scientists in discovering over 20 percent of all human genes. He discovered and named four important gene families, including an insulin-like family of human hormones, a GPCR-like membrane protein family, a family of neural growth factors, and a family of stem cell growth factors. Dr. Tang has an MS in Mathematics, as well as a BS in Biology and Ph.D. in Mathematics, University of Utah.